Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | MURANO update: sustained benefit for time-limited VenR & biomarkers for response in CLL

Arnon Kater • 7 Dec 2019
ASH 2019
Chronic Lymphocytic Leukemia Leukemia Rituximab
MURANO

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, discusses the 4-year analysis of the MURANO trial (NCT02005471); this confirmed the sustained benefit of time-limited venetoclax and rituximab (VenR) in relapsed/refractory chronic lymphocytic leukemia (CLL). In addition, he highlights the potential predictive markers for response to VenR in terms of MRD status that genome and exome-wide study revealed. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Arnon Kater

2:28
GLOW trial updates: predicting outcomes using genomic aberrations and MRD status
Arnon Kater • 6 Oct 2023
1:46
Overcoming T-cell dysfunction
Arnon Kater • 6 Oct 2023
0:53
The future of CLL treatment
Arnon Kater • 6 Oct 2023
2:17
EPCORE CLL-1: epcoritamab in patients with R/R CLL & Richter's transformation
Arnon Kater • 6 Oct 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals